Regentis Biomaterials Ltd. (RGNT) saw its stock plummet 12.12% intraday on Thursday, following its debut on the NYSE American.
The decline came after the company priced its initial public offering at $8 per share, raising $10 million in gross proceeds. The stock opened at $7.40 and fell further to $7.06, reflecting investor skepticism about its market entry.